References
- Peto R, Boreharn J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in 2000 at ages 20–69. Lancet 2000;355:1822.
- Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000 May 20;355(9217):1757–1770.
- Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.
- Mamounas EP, Bryant J, Lembersky BC, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28. J Clin Oncol 2005;23:3686–3696.
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. NEJM 2005;352:2302–2323.
- Roche H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res Treat 2004;88: (Abstract 27).
- Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral blood stem cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005;366:1935–1944.
- Rodenhuis S, Bontenbal M, Beex LVAM, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EGE. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. NEJM 2005;349(1): 7–16.
- Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradisbar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. NEJM 2003;349:17–26.
- Slamon DJ, Lcyland-Joncs B, Shak S, Fuchs H, Paton Y, Bajamonde A, Fleming T, Eiermann W, Woltcr J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that ovcrexpresses HER2. NEJM 2001; 344(11):783–792.
- Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;95\(suppl 1):S6 Abstract 3.
- Miller K, Burstein H, Elias A, et al. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Breast Cancer Res Treat 2005;94\(suppl 1):S61 Abstract 1066.